InflaRx $30 million offering of ordinary shares and pre-funded warrants
The ordinary shares are listed on the Nasdaq Global Market
Davis Polk advised the representative of the several underwriters in connection with the $30 million SEC-registered offering by InflaRx N.V. of 8,250,000 ordinary shares and pre-funded warrants to purchase 6,750,000 ordinary shares. The ordinary shares are listed on the Nasdaq Global Market under the symbol “IFRX.”
InflaRx is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover, develop and commercialize highly potent and specific inhibitors of the complement activation factor C5a and its receptor C5aR.
The Davis Polk corporate team included partner Yasin Keshvargar and associate Michael Schuster. Partner Corey M. Goodman and associate Benjamin Silver provided tax advice. Partner David R. Bauer and associate Adrian Rabin provided intellectual property advice. All members of the Davis Polk team are based in the New York office.